March 23, 2022
COVID-19 Pediatric Vaccines Successfully Met Primary Endpoints (Phase 2/3 Study in Children 6 Months to Under 6 Years)
Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.